Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 204

1.

Landmarks in hormonal therapy for prostate cancer.

Hammerer P, Madersbacher S.

BJU Int. 2012 Oct;110 Suppl 1:23-9. doi: 10.1111/j.1464-410X.2012.11431.x. Review.

2.

Endocrine treatment of prostate cancer.

Tammela T.

J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. Epub 2004 Dec 31. Review.

PMID:
15663992
3.

Intermittent androgen deprivation therapy in advanced prostate cancer.

Alva A, Hussain M.

Curr Treat Options Oncol. 2014 Mar;15(1):127-36. doi: 10.1007/s11864-013-0272-2. Review.

PMID:
24395278
5.

[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].

Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A.

Actas Urol Esp. 2011 Nov-Dec;35(10):565-79. doi: 10.1016/j.acuro.2011.03.011. Epub 2011 Jul 14. Spanish.

PMID:
21757258
6.

[Management of enzalutamide, a new hormonal therapy].

Beuzeboc P, Benderra MA, de La Motte Rouge T.

Bull Cancer. 2014 Jan 1;101(1):107-12. doi: 10.1684/bdc.2013.1880. French.

PMID:
24491670
7.

[Prostate cancer and new hormonal treatments: mechanism of action and main clinical results].

Neuzillet Y, Flamand V, Lebdai S, Villers A, Lebret T.

Prog Urol. 2013 Oct;23 Suppl 1:S34-43. doi: 10.1016/S1166-7087(13)70044-7. Review. French.

PMID:
24314737
8.

Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).

Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR; CaPSURE Investigators.

Cancer. 2006 Apr 15;106(8):1708-14.

9.

Hormonal therapy for prostate cancer: toward further unraveling of androgen receptor function.

Sharifi N.

Anticancer Agents Med Chem. 2009 Dec;9(10):1046-51. Review.

PMID:
19719456
10.

Long-term quality of life in disadvantaged men with prostate cancer on androgen-deprivation therapy.

Sevilla C, Maliski SL, Kwan L, Connor SE, Litwin MS.

Prostate Cancer Prostatic Dis. 2012 Sep;15(3):237-43. doi: 10.1038/pcan.2011.71. Epub 2012 Jan 31.

PMID:
22289781
11.

Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments.

Payne H, Mason M.

Br J Cancer. 2011 Nov 22;105(11):1628-34. doi: 10.1038/bjc.2011.385. Epub 2011 Oct 18. Review.

12.

Long-term effects of androgen deprivation therapy in prostate cancer patients.

Basaria S, Lieb J 2nd, Tang AM, DeWeese T, Carducci M, Eisenberger M, Dobs AS.

Clin Endocrinol (Oxf). 2002 Jun;56(6):779-86.

PMID:
12072048
13.

Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer.

Meyer F, Bairati I, Bédard C, Lacombe L, Têtu B, Fradet Y.

Urology. 2001 Aug;58(2 Suppl 1):71-7.

PMID:
11502453
14.

Radiation therapy and androgen deprivation in the management of high risk prostate cancer.

Dal Pra A, Cury FL, Souhami L.

Int Braz J Urol. 2011 Mar-Apr;37(2):161-75; discussion 176-9. Review.

15.

Combined androgen blockade: the gold standard for metastatic prostate cancer.

McLeod DG, Crawford ED, DeAntoni EP.

Eur Urol. 1997;32 Suppl 3:70-7. Review.

PMID:
9267789
16.

Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.

Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, Middleton R, Sharp SA, Smith TJ, Talcott J, Taplin M, Vogelzang NJ, Wade JL 3rd, Bennett CL, Scher HI; American Society of Clinical Oncology.

J Clin Oncol. 2007 Apr 20;25(12):1596-605. Epub 2007 Apr 2. Review.

PMID:
17404365
17.

[Pathophysiology and therapy of castration-resistant prostate cancer].

Merseburger AS, Kuczyk MA, Wolff JM.

Urologe A. 2013 Feb;52(2):219-25. doi: 10.1007/s00120-012-3054-8. Review. German.

PMID:
23160609
18.

Traditional approaches to androgen deprivation therapy.

Moul JW, Evans CP, Gomella LG, Roach M 3rd, Dreicer R.

Urology. 2011 Nov;78(5 Suppl):S485-93. doi: 10.1016/j.urology.2011.05.051.

PMID:
22054920
19.

Current treatment of advanced prostate cancer.

Ismail M, Gomella LG.

Tech Urol. 1997 Spring;3(1):16-24. Review.

PMID:
9170220
20.

[Hormonal treatment in prostate cancer].

Bastide C, Bruyère F, Karsenty G, Guy L, Rozet F.

Prog Urol. 2013 Nov;23(15):1246-57. doi: 10.1016/j.purol.2013.08.325. Epub 2013 Oct 7. Review. French.

PMID:
24183083

Supplemental Content

Support Center